CYTOVAC AS has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2008. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are HAN HOON, LIFT BIOSCIENCES LTD and NAPAJEN PHARMA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 3 | |
#2 | Australia | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Brazil | 1 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | United Kingdom | 1 | |
#8 | Singapore | 1 | |
#9 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Microbiology |
# | Name | Total Patents |
---|---|---|
#1 | Kirkin Alexei | 10 |
#2 | Jensen Martin Roland | 7 |
#3 | Djandjougazian Karine | 7 |
#4 | Dzhandzhugazyan Karine | 3 |
#5 | Kirkine Alexei | 1 |
#6 | Dzhanzhugazyan Karine | 1 |
#7 | Martin Roland Jensen | 1 |
#8 | Karine Djandjougazian | 1 |
#9 | Alexei Kirkin | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020208054A1 | Method for preparation of cancer/testis antigen-specific t-cells | |
WO2017025584A1 | A cell cultivation method, a cell cultivation vessel, and uses thereof | |
GB201013443D0 | Compositions and methods for producing dendritic cells | |
AU2008203730A1 | Anti-tumor vaccine derived from normal chemically modified cells |